Burning toes, electric-shock sensations, pins and needles, hypersensitivity and deep aching in the feet are common signs of peripheral neuropathy, a form of nerve damage that can become difficult to treat with conventional pain medications. Diabetes is one of the most common causes, but neuropathy in the feet can also result from chemotherapy, vitamin deficiencies, kidney disease, alcohol exposure, autoimmune disorders, infections, spinal or nerve injuries and certain medications. The National Institute of Neurological Disorders and Stroke notes that peripheral neuropathy can arise from many different diseases and injuries, making an accurate diagnosis essential before deciding how the pain should be treated.
Medical marijuana has attracted particular interest because cannabinoids influence pain-processing pathways in both the central and peripheral nervous systems. Clinical trials suggest that some THC-containing cannabis products can modestly reduce neuropathic pain, including pain caused by diabetic peripheral neuropathy. The evidence is promising enough that some chronic-pain guidelines allow cannabinoids as a later treatment option, but it is not strong enough to conclude that marijuana reverses neuropathy or works better than established first-line medications. The most accurate description is that medical cannabis may provide additional symptom relief for selected patients whose nerve pain remains troublesome despite conventional treatment.
Why Nerve Pain Often Starts in the Feet
Peripheral neuropathy frequently begins in the toes and feet because the longest nerves in the body are especially vulnerable to metabolic and toxic injury. In diabetic peripheral neuropathy, symptoms usually develop gradually and symmetrically, often creating a “stocking” pattern that begins at the toes and moves upward. The National Institute of Diabetes and Digestive and Kidney Diseases describes common symptoms as burning, tingling, numbness, pain, weakness and extreme sensitivity to touch. Some people experience severe pain when something as light as a bedsheet touches their feet, while others lose sensation almost completely.
Diabetes is particularly important because peripheral neuropathy can create two problems simultaneously: pain and loss of protective sensation. Someone may have intense burning pain in one part of the foot while being unable to feel a blister, cut or pressure injury somewhere else. NIDDK warns that unnoticed wounds can progress to ulcers and infections, particularly when diabetes also reduces blood flow to the feet. For that reason, treatment should never focus solely on making the feet feel better. Pain control has to occur alongside glucose management, regular foot examinations and attention to wounds, footwear and circulation.
Does Medical Marijuana Actually Help Neuropathic Foot Pain?
The best overall assessment comes from the U.S. Agency for Healthcare Research and Quality, which has conducted a continuing systematic review of cannabis and other plant-based treatments for chronic pain. Its 2025 update concluded that selected people with chronic neuropathic pain may experience small short-term improvements from certain cannabinoid products. Extracted products containing roughly comparable amounts of THC and CBD produced a small reduction in pain severity and a small improvement in function compared with placebo. THC-dominant products also appeared to reduce pain modestly. Nearly half of the studies included in the review involved neuropathic pain, making nerve pain one of the better-researched indications for medical cannabis.
The benefit, however, should be kept in perspective. AHRQ found that improvements were generally small, most studies lasted only several weeks to a few months, and long-term outcomes remain uncertain. Balanced THC/CBD products also substantially increased dizziness and sedation, while THC-dominant products increased dizziness and other adverse effects. CBD alone did not consistently reduce pain or improve function. This evidence helps explain why medical cannabis is better viewed as a possible additional option for difficult neuropathic pain rather than a replacement for established treatment.
The UC San Diego Diabetic Neuropathy Trial
One of the most relevant studies specifically examined people with painful diabetic peripheral neuropathy, the condition most closely associated with burning nerve pain in the feet. Researchers at the University of California, San Diego conducted a randomized, double-blind, placebo-controlled crossover trial involving 16 patients. Participants received placebo cannabis or cannabis containing approximately 1%, 4% or 7% THC during separate laboratory sessions. Investigators measured spontaneous pain, pain caused by light stimulation and cognitive performance for several hours after administration.
Pain decreased in a dose-dependent manner, with the highest-THC cannabis producing the strongest analgesic response. Higher THC exposure also reduced certain types of experimentally evoked pain. That finding provides direct evidence that cannabinoids can influence painful diabetic neuropathy in humans rather than only in laboratory animals. But there was an important tradeoff: the high dose also impaired performance on two of the three neuropsychological tests used by researchers. A later analysis of the same trial found a relationship between THC exposure and pain reduction, reinforcing the possibility of a genuine pharmacological effect while also demonstrating why simply increasing THC indefinitely is not an ideal treatment strategy.
The trial was also extremely small and evaluated only short-term effects following single treatment sessions. It cannot tell us whether inhaled marijuana remains effective after months or years, whether tolerance develops, or whether long-term use improves walking, sleep and overall quality of life. A recent systematic review of cannabis for diabetic peripheral neuropathy similarly concluded that several small trials suggest potential benefit but that differences in cannabinoid formulation, dosing and study design prevent firm conclusions.
Evidence From Other Types of Neuropathic Pain
Cannabis has also been studied in neuropathy caused by conditions other than diabetes. University of California, San Diego researchers conducted a randomized crossover trial in people with painful HIV-associated distal sensory polyneuropathy, another condition that frequently produces burning and painful sensations in the feet. Participants had persistent neuropathic pain despite previously trying other analgesic therapies. Smoked cannabis produced greater pain relief than placebo cannabis during the controlled study.
Researchers associated with UC Davis and UC San Diego have also evaluated vaporized cannabis in neuropathic pain caused by spinal cord injury or disease. In a randomized laboratory experiment involving 42 participants, both lower- and higher-THC vaporized cannabis were compared with placebo. The findings added to a body of evidence suggesting cannabinoid receptors can modulate neuropathic pain across several neurological conditions. These studies do not prove that the same formulation will work for every person with painful feet, but together they strengthen the argument that neuropathic pain is one of the chronic-pain categories in which THC-containing cannabis has a plausible and clinically measurable analgesic effect.
What remains much less certain is whether cannabis is particularly effective for chemotherapy-induced peripheral neuropathy. The National Cancer Institute recognizes chemotherapy-induced peripheral neuropathy as a common source of pain, numbness and tingling in the hands and feet, sometimes continuing long after cancer treatment ends. Cannabis is frequently discussed by patients with cancer, but evidence specifically showing that botanical marijuana effectively treats chemotherapy-related foot neuropathy remains insufficient. Duloxetine has substantially more established clinical support for painful chemotherapy-induced neuropathy.
THC, CBD or a Balanced Product?
Current evidence does not support the widespread assumption that CBD alone is the most effective cannabinoid for nerve pain. In AHRQ’s 2025 review, purified or synthetic oral CBD did not significantly improve chronic pain intensity or function compared with placebo. By contrast, formulations containing comparable quantities of THC and CBD—approximately a balanced ratio—and THC-dominant products produced small improvements in pain, most commonly in neuropathic-pain populations.
That does not mean everyone with burning feet should seek the highest-THC marijuana available. Increasing THC also increases the likelihood of intoxication, dizziness, impaired concentration, sedation and problems with balance. This is particularly relevant because peripheral neuropathy itself can impair balance and increase fall risk. NIDDK notes that neuropathy can interfere with gait and position sensing, while THC can independently impair coordination and psychomotor performance. A strong THC product might therefore reduce burning pain while simultaneously making walking less safe.
CBD-dominant products may still be considered in selected patients when minimizing intoxication is a priority, but expectations should be realistic. CBD also is not pharmacologically inert. The FDA warns that CBD can cause sleepiness, affect liver function and interact with other prescription medications. People already taking gabapentin, pregabalin, antidepressants, blood thinners, antiseizure medications or other drugs should therefore have their complete medication list reviewed rather than assuming a CBD product is automatically interaction-free.
Where Cannabis Fits Compared With Standard Neuropathy Treatment
Current diabetes guidelines do not place cannabis among the standard first-line medications for painful diabetic neuropathy. The American Diabetes Association’s 2026 Standards of Care recommend gabapentinoids such as pregabalin or gabapentin, serotonin-norepinephrine reuptake inhibitors such as duloxetine, tricyclic antidepressants and sodium-channel blockers as initial pharmacological treatment categories. The ADA also emphasizes treating associated sleep and mood disorders and considering combination therapy when a single treatment does not provide adequate relief.
Other clinical guidelines take a similarly cautious position. NICE recommends amitriptyline, duloxetine, gabapentin or pregabalin as initial therapy for most neuropathic pain and specifically advises clinicians not to initiate Cannabis sativa extract in nonspecialist settings unless advised by a specialist. The Canadian Pain Society has historically positioned cannabinoids further down its neuropathic-pain treatment pathway, after better-established first-line therapies.
An international BMJ clinical guideline took a somewhat more permissive approach, issuing a weak recommendation for a trial of non-inhaled medical cannabis or cannabinoids when standard treatment for chronic cancer or noncancer pain has not provided adequate relief. The recommendation was intentionally weak because the average improvements in pain, sleep and physical functioning were small and had to be balanced against adverse effects. Taken together, these guidelines suggest a reasonable place for cannabinoids as an individualized additional treatment rather than the automatic first treatment for painful feet.
Cannabis Can Reduce Pain Without Repairing the Nerves
Perhaps the most important distinction for someone with neuropathy is the difference between treating pain and treating the underlying nerve damage. Cannabis studies primarily measure changes in pain perception. They do not demonstrate that marijuana restores damaged peripheral nerves, reverses diabetic neuropathy or prevents diabetic foot complications. A person whose burning improves after THC may still have exactly the same loss of protective sensation and the same risk of developing an unnoticed blister or ulcer.
Conventional neuropathy medications have similar limitations: NIDDK notes that medicines used to control peripheral neuropathic pain generally relieve symptoms rather than reverse existing nerve damage. For diabetic neuropathy, addressing the underlying disease remains crucial. ADA recommends optimizing glucose management and managing weight, blood pressure and blood lipids to reduce the risk or slow progression of diabetic neuropathy. Daily foot care remains necessary even when pain treatment works extremely well.
This distinction becomes particularly important if medical cannabis makes the feet feel substantially better. Reduced pain should not be interpreted as evidence that an ulcer has healed, circulation has improved or sensation has returned. People with diabetes-related neuropathy should continue inspecting their feet every day and seek medical attention for wounds, redness, swelling, warmth, drainage or other changes even if cannabis is successfully controlling their pain.
Risks That Matter Specifically for People With Foot Neuropathy
Dizziness and sedation are among the most consistently documented adverse effects of cannabinoid pain treatment. In AHRQ’s 2025 review, roughly balanced THC/CBD products were associated with more than a threefold increase in dizziness and approximately a fivefold increase in sedation compared with placebo. For someone whose neuropathy already causes instability, reduced position sensing or muscle weakness, those effects can translate into a meaningful fall risk.
Medication combinations also matter. Many people with neuropathy already take gabapentin, pregabalin, duloxetine, tricyclic antidepressants, sleep medications or opioids. THC can add to sedation and impairment caused by other central nervous system depressants, while CBD may alter the metabolism of certain medications. FDA guidance specifically cautions that cannabinoid products can interact with other drugs and that combining CBD with substances that slow brain activity can increase drowsiness and potentially contribute to injury.
People with significant cardiovascular disease, a history of severe cannabis anxiety or psychosis, frequent falls or complicated medication regimens deserve particularly careful assessment. Driving should also be avoided while impaired. FDA warns that cannabis and cannabis-derived compounds can interfere with alertness and make driving dangerous.
What About Cannabis Creams and Topicals for the Feet?
Topical CBD and THC creams are attractive for neuropathy because they appear to offer localized treatment without significant intoxication. Unfortunately, clinical evidence for topical cannabinoid products remains considerably weaker than the marketing surrounding them. AHRQ concluded that evidence for topical CBD and many whole-plant cannabis preparations was insufficient to determine their effectiveness for chronic pain. The fact that a cream contains CBD does not mean enough cannabinoid reaches the relevant peripheral nerves to produce a clinically meaningful effect.
Topicals also deserve special caution in people with diabetic feet. Cannabis creams, balms or oils should not distract from evaluation of wounds, infections or skin breakdown. Anyone with reduced sensation can unknowingly develop serious foot injuries, and applying an unregulated topical product to damaged skin may complicate assessment. Persistent burning, new numbness or worsening foot pain deserves diagnosis rather than simply repeated treatment with over-the-counter cannabis products.
The Bottom Line
Medical marijuana may help reduce nerve pain in the feet for some people, and neuropathic pain is one of the areas where cannabinoid therapy has meaningful clinical evidence. Small randomized studies—including a UC San Diego trial specifically involving painful diabetic peripheral neuropathy—have found dose-related pain relief from THC-containing cannabis. Larger evidence reviews from AHRQ conclude that balanced THC/CBD and THC-dominant products can produce small short-term reductions in predominantly neuropathic pain, although dizziness, sedation and other adverse effects are common. CBD alone has not demonstrated the same consistent analgesic benefit.
Cannabis should therefore be viewed as a possible symptom-management tool, not a cure for neuropathy. Established treatments such as gabapentin, pregabalin, duloxetine and certain tricyclic antidepressants remain better supported as initial therapies for diabetic nerve pain, and controlling the disease causing the neuropathy remains essential. For people whose foot pain remains severe despite appropriate conventional treatment, a carefully monitored cannabinoid trial may be reasonable where medically and legally available. The best outcome is not simply making the burning disappear—it is reducing pain while preserving balance, cognition, mobility and the ability to protect the feet from further injury.
